ReviewTranslational gastroenterology and hepatology2019
Adjuvant therapy with imatinib in gastrointestinal stromal tumors (GISTs)-review and perspectives.
Review in Translational gastroenterology and hepatology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 53 citations in OpenAlex.
- A Case Report and Literature Review of a Rectal Gastrointestinal Stromal Tumor.ACG case reports journal · 2026Article
- Duration-dependent effects of adjuvant imatinib on recurrence-free and overall survival after resection of gastrointestinal stromal tumors: a systematic review and meta-analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Incidental finding of gastrointestinal stromal tumor in appendix.Journal of surgical case reports · 2026Article
- A CT-based radiomics model for preoperative risk stratification of gastrointestinal stromal tumors.Frontiers in oncology · 2026Article
- Surgical treatment of gastrointestinal stromal tumors.Journal of medicine and life · 2026Review
- The R.O.A.D. to precision medicine.NPJ digital medicine · 2024Article
- Two Decades of Gastrointestinal Stromal Tumor Management With First-Line Treatment: A Case Report.Cureus · 2024Article
- Adjuvant therapy for rare rectal gastrointestinal stromal tumors: A case report.Clinical case reports · 2024Article
- Review
- Deep learning predicts patients outcome and mutations from digitized histology slides in gastrointestinal stromal tumor.NPJ precision oncology · 2023Article
- Adjuvant therapies in stages I-III epidermal growth factor receptor-mutated lung cancer: current and future perspectives.Translational lung cancer research · 2023Review
- Rectal Gastrointestinal Stromal Tumors.Cureus · 2023Article
- Jejunal gastrointestinal stromal tumour: a rare cause of severe small bowel bleeding.Przeglad gastroenterologiczny · 2023Article
- Premature senescence and cardiovascular disease following cancer treatments: mechanistic insights.Frontiers in cardiovascular medicine · 2023Review
- Surgery for mesenchymal neoplasms of the esophagus: experience over 2 decades from a tertiary healthcare center in India.Updates in surgery · 2022Article
- Primary Localized Gastrointestinal Stromal Tumors: Medication Adherence and Prognosis According to Gender.Patient preference and adherence · 2022Article
- BRD9 inhibition promotes PUMA-dependent apoptosis and augments the effect of imatinib in gastrointestinal stromal tumors.Cell death & disease · 2021Article
- Humeral metastasis as the only recurrence of a 5-year resected gastrointestinal stromal tumor: a case report.Journal of medical case reports · 2021Article
- Gastrointestinal Stromal Tumor: An Uncommon but Serious Cause of Gastrointestinal Bleeding.Journal of medical cases · 2021Article
- CT Radiomics Model for Discriminating the Risk Stratification of Gastrointestinal Stromal Tumors: A Multi-Class Classification and Multi-Center Study.Frontiers in oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumor of the gastrointestinal (GI) tract. Most of them (>75%) are driven by an oncogenic initiating event involving activating mutations of the genes encoding for tyrosine kinase, KIT or platelet derived growth factor receptor alpha (PDGFRA). Efficacy of the tyrosine kinase Inhibitor imatinib is now well established for advanced disease. For localized GISTs, 3 years treatment is the recommended adjuvant therapy for high risk patients. Whether a longer duration and selection of patients for this adjuvant therapy in localized GISTs remains is not yet established (PERSIST-5 study). Similarly, it will be important to further refine the definition of the population of GIST patients at high risk of relapse including molecular criteria (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.